Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CFO Mark Ragosa Sells 12,000 Shares

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) CFO Mark Ragosa sold 12,000 shares of the firm’s stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of $41.89, for a total value of $502,680.00. Following the sale, the chief financial officer owned 19,086 shares of the company’s stock, valued at $799,512.54. This represents a 38.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Mark Ragosa also recently made the following trade(s):

• On Monday, December 8th, Mark Ragosa sold 42,841 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $41.49, for a total value of $1,777,473.09.
• On Wednesday, November 12th, Mark Ragosa sold 19,900 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $40.94, for a total value of $814,706.00.
• On Tuesday, October 28th, Mark Ragosa sold 100 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $41.00, for a total value of $4,100.00.

Kiniksa Pharmaceuticals International Trading Up 2.3%

KNSA stock opened at $42.67 on Friday. Kiniksa Pharmaceuticals International, plc has a twelve month low of $17.82 and a twelve month high of $44.42. The company has a market capitalization of $3.23 billion, a P/E ratio of 94.82 and a beta of 0.04. The firm has a 50 day simple moving average of $41.26 and a 200-day simple moving average of $36.31.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its quarterly earnings results on Tuesday, October 28th. The company reported $0.23 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.31 by ($0.08). The company had revenue of $180.86 million during the quarter, compared to analyst estimates of $166.64 million. Kiniksa Pharmaceuticals International had a net margin of 6.01% and a return on equity of 7.46%. The company’s revenue was up 61.2% on a year-over-year basis. During the same period in the prior year, the company earned ($0.18) earnings per share. On average, research analysts predict that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. SG Americas Securities LLC increased its position in Kiniksa Pharmaceuticals International by 288.6% in the fourth quarter. SG Americas Securities LLC now owns 541,396 shares of the company’s stock worth $22,333,000 after buying an additional 402,078 shares during the period. Sound View Wealth Advisors Group LLC grew its position in shares of Kiniksa Pharmaceuticals International by 16.2% during the fourth quarter. Sound View Wealth Advisors Group LLC now owns 14,792 shares of the company’s stock worth $610,000 after acquiring an additional 2,063 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its holdings in shares of Kiniksa Pharmaceuticals International by 4.9% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 16,424 shares of the company’s stock worth $701,000 after acquiring an additional 771 shares during the period. JPMorgan Chase & Co. lifted its position in Kiniksa Pharmaceuticals International by 42.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 192,456 shares of the company’s stock valued at $7,473,000 after purchasing an additional 57,174 shares during the last quarter. Finally, Danske Bank A S acquired a new position in Kiniksa Pharmaceuticals International during the 3rd quarter valued at about $1,180,000. Institutional investors and hedge funds own 53.95% of the company’s stock.

Wall Street Analysts Forecast Growth

KNSA has been the subject of several research analyst reports. TD Cowen assumed coverage on Kiniksa Pharmaceuticals International in a report on Monday, September 29th. They issued a “buy” rating and a $60.00 price objective for the company. Wall Street Zen downgraded Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a report on Sunday, November 2nd. Weiss Ratings restated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research note on Wednesday, October 8th. The Goldman Sachs Group boosted their target price on shares of Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Finally, Zacks Research cut shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a report on Monday, October 6th. Six analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat, Kiniksa Pharmaceuticals International presently has an average rating of “Moderate Buy” and a consensus target price of $52.00.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.